Interference Control Panel for Blood Assay Validation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PCR-based assays face interference from blood components like hemoglobin, triglycerides, and anticoagulants, leading to unreliable test results due to inhibition of chemical reactions, which complicates the detection of nucleic acids and requires time-consuming and unreliable quality control methods.
Innovation Solution
A calibrated interference panel with known concentrations of potential interfering substances is used to validate the assay system by adding a known analyte of interest, allowing for the quantification of interference effects and setting acceptance criteria, thereby ensuring accurate and reliable results.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PCR-based assays are used to detect nucleic acids in blood samples, then detection sensitivity is improved, but interference from blood components (hemoglobin, triglycerides, anticoagulants) increases, leading to unreliable results
Solution Approach 1:
The patent introduces an interference panel as an intermediary substance that contains known concentrations of interfering components (hemoglobin, triglycerides, anticoagulants). This panel acts as a mediator to model and quantify interference effects in the assay system, allowing researchers to understand and compensate for the impact of blood components without directly eliminating them from the sample matrix.
Solution Approach 2:
The patent employs parameter changes by systematically varying the concentrations of interfering substances in the interference panel members. By creating panels with different levels of interference (e.g., low, medium, high concentrations of hemoglobin or triglycerides), the study quantifies how interference levels affect assay performance and establishes thresholds for acceptable results.
2Reliability
If sample preparation methods are implemented to remove inhibitory substances, then interference is reduced, but the complexity and time required for processing increases
Solution Approach 1:
Instead of physically removing interfering substances from complex blood samples through lengthy purification procedures, the patent creates simplified copies of interference conditions using the interference panel. These panels contain defined mixtures of interfering substances that replicate the effect of complex blood matrices without requiring complex sample preparation, thus reducing processing complexity while maintaining reliability assessment.
3Measurement precision
If quality control methods are used to monitor interference, then result accuracy is improved, but the time required for testing increases
Solution Approach 1:
The interference panel performs preliminary action by pre-establishing known interference conditions before actual sample testing. By preparing panels with predetermined concentrations of interfering substances and running them through the assay system in advance, the study determines interference thresholds and compensation factors that can be applied to subsequent patient samples, reducing the need for time-consuming iterative quality control measurements.
4Difficulty of detecting and measuring
If internal controls are added to PCR reactions to monitor inhibition, then detection of inhibitors is improved, but the complexity of the assay system increases
Solution Approach 1:
The interference panel serves multiple functions simultaneously: it acts as a quality control reference, an interference quantification standard, and a system validation tool. Rather than adding separate internal controls for each possible interferent, the panel provides a universal reference that can detect and quantify the effects of various blood components (hemoglobin, triglycerides, anticoagulants) on the assay system, reducing overall complexity while improving inhibitor detection capability.
Data Source
AI summary
The invention relates to quality control of analytical assays, particularly NAT assays of blood samples containing nucleic acids. A control panel containing quantified amounts of substances known to interfere with an analytical assay is used and compared with a reference sample in the analytical assay. A comparison of the assay results interference panel validates the assay and can serve as a periodic quality control check for the analytical assay as well as related methods and protocols. The use of the control panel of the invention can also determine whether interfering substances are present and establish under what conditions the analytical assay reliable.